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Cyclin-dependent kinase 4 (CDK4)/cyclin D has a key role in reg-
ulating progression through late G1 into S phase of the cell cycle.
CDK4-cyclin D complexes then persist through the latter phases of
the cell cycle, although little is known about their potential roles.
We have developed small molecule inhibitors that are highly selec-
tive for CDK4 and have used these to define a role for CDK4-cyclin
D in G2 phase. The addition of the CDK4 inhibitor or small inter-
fering RNA knockdown of cyclin D3, the cyclin D partner, delayed
progression through G2 phase and mitosis. The G2 phase delay was
independent of ATM/ATR and p38MAPK but associated with ele-
vated Wee1. The mitotic delay was because of failure of chromo-
somes to migrate to the metaphase plate. However, cells eventually
exited mitosis, with a resultant increase in cells with multiple or
micronuclei. Inhibiting CDK4 delayed the expression of the chro-
mosomal passenger proteins survivin and borealin, although this
was unlikely to account for the mitotic phenotype. These data pro-
vide evidence for a novel function for CDK4-cyclin D3 activity in S
andG2 phase that is critical for G2/M progression and the fidelity of
mitosis.
Cyclin-dependent kinase 4 (CDK4)3 binds cyclin D to provide a
mechanistic link between extracellular growth signals and the initiation
of entry into S phase fromG0/G1. Its role in this pathway is to phospho-
rylate and inactive members of the retinoblastoma protein (Rb) family,
which includes Rb, p107, and p130 (1, 2). This phosphorylation allows
the release and activation of E2F transcription factors, which in turn
up-regulates the genes required for S phase. CDK4 is regulated by cyclin
D binding, phosphorylation, and association with inhibitory protein
subunits of the INK4 family. Unlike other CDK-cyclin complexes, it is
present at constant levels throughout the cell cycle in continuously pro-
liferating cells, although its activity varies.
Mutations in theCDK4-cyclinD/Rb pathway are commonly found in
many types of cancer. A number of viral oncogenes directly target the
inactivation of Rb, and overexpression of cyclin D is common in breast
cancer. This is particularly relevant in melanoma, where germ line
mutations of the cyclin-dependent kinase inhibitor p16INK4A or CDK4
mutations that disrupt p16 binding are carried inmelanoma-prone kin-
dred (for review, see Ref. 3). In addition, somatic p16INK4A loss or muta-
tion occurs in up to 30% of melanomas (3, 4), and a small proportion of
melanomas carry somatic CDK4mutations that disrupt p16INK4A bind-
ing (4, 5). This points to the importance of the cyclin D/CDK4/Rb path-
way in controlling G0/G1 cell cycle progression. However, the role of
CDK4-cyclin D in the phosphorylation and inactivation of Rb can in
some cases be effectively substituted by cyclin E-CDK2 (6), and knock-
out mouse models have shown redundancy of CDK4 and CDK6,
whereas knock-out of both had only minimal effect on the cell cycle of
cells (7, 8). These data indicate that CDK4 is not essential for cell cycle
progression, so then why is the CDK4-cyclin D pathway often de-regu-
lated in cancer? An explanation may be that CDK4 has important func-
tions in addition to the G1 phase phosphorylation of Rb. A peak of
CDK4-cyclin D3 activity has been demonstrated during S/G2 phase (9),
suggesting that there are likely to be additional functions and substrates
for CDK4 outside of G1 phase. This hypothesis is strengthened by the
finding that CDK4-cyclin D3 can phosphorylate nucleolin, a protein
that is implicated in the transcription and processing of ribosomal RNA
and nucleolar structure as well as additional unidentified proteins (10).
To define the role for CDK4-cyclin D, we have produced small mol-
ecule inhibitors of CDK4-cyclinD and used siRNAknockdown of cyclin
D3 to demonstrate specificity of the inhibitors. Using these, we demon-
strate here that CDK4 plays a critical role in G2/M phase progression.
Loss of CDK4-cyclin D3 activity produced a transient delay in early G2
phase before to the activation of CDK2-cyclin A inG2 phase andCDK1-
cyclin B1 at G2/M. This delay does not appear to operate through the
known G2/M checkpoints mechanisms, the ATM/ATR, and the p38
MAPK mediated pathways that operate in response to a variety of cel-
lular stresses. Inhibition of CDK4 also delayed transit through mitosis,
with 30% of cells progressing through an aberrant mitosis to produce
cells withmultiple nuclei or containingmicronuclei.We also observed a
delay in the G2/M phase expression of two gene products critical for the
fidelity of partitioning of the replicated genome in mitosis, the chromo-
somal passenger proteins survivin and borealin. However, these pro-
teins accumulated to relatively normal levels in cells that reached mito-
sis, suggesting that these were unlikely to contribute significantly to the
aberrant mitosis observed. Our data indicate that inhibition of CDK4
activity during S andG2 phase delays G2/Mprogression and reduces the
fidelity ofmitosis, providing strong evidence that CDK4 plays an impor-
tant role outside of G1 and Rb phosphorylation.
EXPERIMENTAL PROCEDURES
Materials—Caffeine, the p38MAPK inhibitor SB203580, and etopo-
side were purchased from Sigma-Aldrich. CDK4 inhibitors (RO
0506220 and RO 0505124) and two structurally similar compounds that
show no CDK4 kinase inhibition (RO 0507574 and RO 0507304) were
synthesized by Discovery Chemistry Group (Hoffmann-La Roche). All
other chemicals used were of analytical grade.
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Cell Culture and Synchrony—All cells were cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 3mMHEPES
and 10% (v/v) Serum Supreme (BioWhittaker) in tissue culture incuba-
tors set at 5% CO2 and 37 °C. Hydroxyurea and double thymidine block
release synchronizations were performed as described in Gabrielli et al.
(11). Cells were treated with CDK4 inhibitors 1 h after release from
synchrony unless stated otherwise and harvested at the indicated times.
Growth assays were performed by 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) assay as described previously (12).
Assays for mycoplasma were carried out monthly to ensure that all of
the cultured cells were free of contamination.
CDK4 Inhibitor Kinase Screen—Kinase assays were performed by
FlashPlateTM assays (PerkinElmer Life Sciences). FlashPlate assays were
performed using recombinant human cyclin B-CDK1, human cyclin
E-CDK2, or human cyclin D1-CDK4 complexes. Glutathione S-trans-
ferase (GST)-cyclin E, CDK2, GST-cyclin B, CDK1, GST-CDK4k, and
cyclin D1 cDNA clones in baculovirus vectors were provided by Dr. W.
Harper at the Baylor College of Medicine, Houston, TX. Proteins were
co-expressed in High FiveTM insect cells, and the complex was purified
on glutathione-Sepharose resin (Amersham Biosciences). A 6histi-
dine-tagged truncated form of Rb protein (amino acid 386–928) was
used as the substrate for the cyclin D1-CDK4, cyclin B-CDK1, and the
cyclin E-CDK2 assays (the expression plasmid was kindly provided by
Dr. Veronica Sullivan, Department of Molecular Virology, Roche
Research Centre, Welwyn Garden City, UK). Protein expression was
under the control of an isopropyl 1-thio--D-galactopyranoside-induc-
ible promoter in an M15 Escherichia coli strain. Cells were lysed by
sonication, and purification was carried out by binding lysates at pH 8.0
to a nickel-chelated agarose column pretreated with 1 mM imidazole.
The resin was then washed several times with incrementally decreasing
pH buffers to pH 6.0 and eluted with 500 mM imidazole. Eluted protein
was dialyzed against 20mMHEPES, pH 7.5, 30% glycerol, 200mMNaCl,
and 1 mM dithiothreitol. Purified Rb fusion protein stocks were quanti-
tated for protein concentration, separated into aliquots, and stored at
70 °C.
For all three kinase assays, 96-well FlashPlates were coated with Rb
protein at 10 g/ml using 100 l/well. Plates were incubated at 4 °C
overnight or at room temperature for 3 h on a shaker. To control for
nonspecific phosphorylation, one row of wells was coated with 100
l/well coating buffer (20 mM HEPES, 0.2 M NaCl). Plates were then
washed twice with wash buffer (0.01% Tween 20 in phosphate-buffered
saline). Compounds to be tested were added to the wells at 5 final
concentrations. Reactions were initiated by the immediate addition of
40 l of reaction mix (25 mM HEPES, 20 mM MgCl2, 0.002% Tween 20,
2mM dithiothreitol, 1MATP, 4 nM [33P]ATP) and a sufficient amount
of enzyme to give counts that are at least 10-fold above background.
Plates were incubated at room temperature on a shaker for 30 min.
Plates were washed four times with the wash buffer, sealed, and counted
on the TopCount Scintillation Counter.
The protein kinase B, p38, and MAPK and tyrosine kinases were
assayed in-house at Roche. Assays for these kinases are based on IMAP
TechnologyTM (Molecular Device Corp.) that enables quantitation of
kinase activity via preferential binding of phosphorylated fluorescent
peptide substrates to immobilized metal beads. These reactions were
carried out at ATP concentrations of 3 the Km for the respective
enzyme. Counter-screening against the other kinases was carried out
using fluorescence resonance energy transfer assays at the Km for ATP.
siRNA Design and Transfection—The Ambion Silencer siRNA con-
struction kit (Ambion) was used to produce siRNAs against cyclin D3
andD1. The following target sequences were identified and appropriate
oligonucleotides were constructed as per manufacturer’s instructions.
Three cyclin D3 target sequences were identified, and Blast searches
were performed to ensure that the sequences did not contain significant
homology to any other known genes. The sequences were: Sequence 1,
AAGGATCTTTGTGGCCAAGGA; sequence 2, AAGATGCTGGCT-
TACTGGATG; sequence 3, AATTGGATACATACACCAGCA. All
three produced similar levels of specific cyclin D3 knockdown, and
siRNA against sequence 1 was then used for all remaining experiments.
In addition, a scrambled version of sequence 1 (NS sequence,
AAGAAGTTAGTCCGATGCGTG), which contained no homology to
CDK4 or any known genes, was used as a control.
siRNA transfection were performed as per the manufacturer’s
instructions. Where indicated, cells were synchronized by blocking
overnight with 2mM hydroxyurea, and released into S phase the follow-
ing day. They were then analyzed by live cell imaging, immunofluores-
cence, and immunoblotting.
RNA Isolation and cDNA Synthesis—Cells were lysed using TRIzol
reagent (Invitrogen), and total RNA was extracted as per the manufac-
turer’s instruction. The RNA was quantified by a Smart Spec spectro-
photometer (Bio-Rad) at a wavelength of 260/280 nm, and the extract
was stored at 70 °C until cDNA synthesis. cDNA was synthesized
using Superscript III (Invitrogen) as per the manufacturer’s instruction.
An equal amount of total RNAwas used for cDNA synthesis in each set
of experiment.
Quantitative PCR—Quantitation of survivin cDNA and an internal ref-
erencecDNA(-actin)wasperformedusinga fluorescencebasedreal-time
detection method (ABI PRISM 7700 Sequence Detection System (Taq-
man), Applied Biosystems) as per themanufacturer’s instruction. Briefly, a
dual-labeled fluorescent oligonucleotide probewas used that annealed spe-
cifically within the forward and reverse primers. The PCR reaction con-
sisted of 600 nM concentrations of each primer, 200 nMprobe, 1Taqman
Universal PCR master mix containing 200 M each dATP, dCTP, dGTP,
400MdUTP, 5.5mMMgCl2, 1 unit ofAmpErase uracilN-glycosylase to a
final volume of 20l (all reagents PerkinElmer Life Sciences). Cycling con-
ditions were 50 °C for 2 min and 95 °C for 10 min followed by 40 cycles at
95 °C for 15 s and 60 °C for 1min. The sequences for the PCR primers area
as follows. Survivin: forward primer, 5-TGCCCCGACGTTGCC-3;
reverse primer, 5-CAGTTCTTGAATGTAGAGATGCGGT-3; probe,
5-(6-Fam)CCTGGCAGCCCTTTCTCAAGGACC-(Tamra)-3. -Ac-
tin: forward primer, 5-AGCCTCGCTTTGCCGA-3, reverse primer, 5-
CTGGTGCCTGGGGCG-3, probe, 5-(6-Fam)CCGCCGCCCGT
CCACACCCGCC(Tamra)-3.
Biochemical Analysis—Cells were lysed in NETN (20mMTris-HCl, pH
8, 1mMEDTA, 100mMNaCl, 0.5%Tween 20) supplementedwith 150mM
NaCl, 10mMNaF, 0.1mM sodium orthovanadate, 1mM phenylmethylsul-
fonyl fluoride, and protease inhibitor mixture (Sigma-Aldrich). After 20
minon ice, theDNAwaspelleted, and lysateswere resolvedon appropriate
SDS-polyacrylamidegel electrophoresisplates, transferred tonitrocellulose
membranes, and immunoblotted for proteins using antibodies against
borealin (a gift from Professor Earnshaw, Edinburgh (13)), pRb, Wee1,
phosphotyrosine 15 CDK1/2 (PY15) (Cell Signaling), -tubulin (Sigma-
Aldrich), survivin, cyclin D3, cyclin A, CDK4, CDK2 (Santa Cruz Biotech-
nology), and cyclin B1 (11) using the appropriate horseradish peroxidase-
conjugated secondary antibody (Zymed Laboratories Inc.) and enhanced
chemiluminescence (PerkinElmer Life Sciences) for detection.
Immunofluorescent Staining—Cells were grown on glass coverslips.
For immunostaining, cells werewashedwith phosphate-buffered saline,
fixed with 100%20 °C methanol, and stored at20 °C until required.
Coverslipswere allowed to air-dry and then rehydratedwith phosphate-
buffered saline containing 0.1%Tween 20 and 3%bovine serumalbumin
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for 1 h at room temperature. The cells were stained with anti--tubulin,
survivin, human autoimmune serum (h-ACA) to detect kinetochores,
and 4,6-diamidino-2-phenylindole (0.1 g/ml) for DNA. Coverslips
were mounted on glass slides supplemented with Vectashield (Vector
Laboratories, Burlingame, CA) to maintain fluorescence. Cells were
visualized using a Carl Zeiss Axioskop 2 plus microscope, and images
were captured using aCarl Zeiss AxioCam2 camera andAxiovision and
Adobe Photoshop software.
Flow Cytometry—For flow cytometric analysis (FACS), floating and
attached cells were collected for analysis. Cells were fixed in ice-cold
70% ethanol and stored at 20 °C. Samples were then washed once in
phosphate-buffered saline and re-suspended in DNA staining solution
consisting of 5 g/ml propidium iodide and RNase A (0.5 mg/ml) in
phosphate-buffered saline. The stained cells were filtered through
37-m silk gauze, and the single-cell suspensions were analyzed on a
FACSCalibur (BD Biosciences) using Cell Quest, with the proportion of
cells in each cell cycle stage and subdiploid population calculated using
the ModFit analysis package (Verity Software House, Topsham, ME).
Bromodeoxyuridine (BrdUrd) staining was performed as described pre-
viously (14) as was MPM-2 staining (15).
Live Cell Imaging—Cells were seeded the day before the experiment
on 6- or 12-well plates at50% confluence. Live cell imaging was per-
formed using a Zeiss Cell Observer. Images were captured every 10min
for the duration of the cell cycle using Zeiss Axiovision software. Single
cell analysis was performed by individually following each cell through
each frame and observing the number of frames required to complete
each distinct phase. Entry into mitosis was identified when the cells
rounded up, and exit from mitosis was when anaphase and cytokinesis
were observed.
RESULTS
Identification of Highly Selective Small Molecule Inhibitors of CDK4—
The diaminothiazole series of compounds were identified as a result of a
screen for cyclin-cyclin-dependent kinase inhibitors (see “Experimental
Procedures” for details of the screen).Modifications to the compound class
produced two potent and selective CDK4 inhibitors with IC50 values of 20
nM for recombinant CDK4-cyclin D in vitro that were 100-fold more
potent for CDK4 comparedwith CDK1 and 2 in vitro (Fig. 1, Table 1). The
inhibitors are reversible andbind theATPpocketof thekinases.A screenof
128 protein kinases was performed commercially using RO0505124 at a 1
M concentration to assess the potential number of kinases that may be
inhibited by these compounds. Eleven kinases from different families were
inhibited 90% at this dose, demonstrating the relatively high degree of
selectivity of the drugs but indicating that other kinasesmay also be targets.
To demonstrate that these compounds inhibit CDK4 in cells, a number of
cell lines with or without functional Rb were tested. Inhibition of CDK4
shouldproduceaG1delay andreduction inRbphosphorylation incells that
contain functional Rb.HeLa cells that do not contain functional Rb did not
display a G1 arrest after 24 h of treatment with 2M RO0506220, whereas
SK-Mel-13 cells that have functional Rb had a strong G1 arrest (Fig. 2A).
Similar data were obtained with both RO0506220 and RO0505124,
whereas the inactive analogues had no effect on either cell lines. Later
experiments were performed with RO0506220 and RO0505124 and are
denoted as CDK4 inhibitor (CDK4i). Asynchronously growing HCT-116
cells, which contain functional Rb, were treated for 24 h with increasing
doses of CDK4i. Cells were then either pulsed with BrdUrd and harvested
for FACS analysis, or samples were collected to examine Rb phosphoryla-
tion status. A dose of 3.9 M was required to reduce S phase to 50% of
control levels (IC50),with a significant reduction in the level ofRbphospho-
rylation also observed (Fig. 2, B and C). Higher doses further inhibited
BrdUrd incorporation and Rb phosphorylation. These data demonstrated
that drug treatment arrested cells in G1 phase, blocking progression into S
phase. Interestingly, the proportion of G2/M phase cells appeared to either
remain constant or increased after CDK4i treatment, whereas it would be
expected to decrease if the drugs caused only a G1 phase arrest. An addi-
tional 9 cell lineswere tested, and the IC50 values for inhibitionof S phase in
these cells ranged from 0.5 to 8 M (Table 2). The much higher drug con-
centrations required for the in vivo inhibition of CDK4 activity compared
with in vitro is likely tobea consequenceofnonspecific bindingof thedrugs
reducing their effective concentrations. At IC50 concentrations the drugs
caused little toxicity even after 3 days of treatment. Higher doses caused a
moderate increased toxicity. To avoid any potentially nonspecific toxic
effects, a dose of 2–4MCDK4i was chosen as an appropriate concentra-
tion for the remainder of the experiments, as this provided strong in vivo
inhibition of CDK4 without affecting CDK1 or CDK2 activity.
Inhibition of CDK4 Delays Cells in G2 Phase—Previous work had
provided evidence that CDK4-cyclin D3 was active in S and G2 phases
and that inhibiting this activity caused a G2/M phase delay (9). To ana-
lyze the effects of the CDK4 inhibitors on cell cycle progression beyond
the Rb-dependent G1 arrest, cells were synchronized and then treated
during early S phase with CDK4i. The progression of cells through the
remainder of the cell cycle was monitored using flow cytometry, bio-
chemical analysis, and time-lapse microscopy. Upon release, cells were
FIGURE 1. The chemical structures for the two
active CDK4 inhibitors RO0505124 and
RO0506220 are shown.
TABLE 1
In vitro inhibition of kinases by CDK4i
Kinase Inhibition IC50RO0505124 RO0506220
nM
CDK4-cyclin D 20 20
CDK2-cyclin E 2,360 4,144
CDK1-cyclin B 3,042 1,973
c-Met 20,000 20,000
Src 3,210 3,480
Lck 100,000 100,000
Insulin-like growth factor 1 receptor 22,000 20,000
Insulin receptor 71,000 24,000
p38 MAPK 29,000 100,000
Protein kinase B/AKT 200,000 200,000
c-Jun NH2-terminal kinase 50,000 50,000
Extracellular signal-regulated kinase 1 100,000 100,000
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treated at various stages through S phasewith orwithout 2MCDK4i or
inactive control. Treatment 2 h post-release during early S phase
resulted in HeLa cells delaying progression through mitosis by 4 h.
These cells remained in G2/M at 12 h post-release when the untreated
controls had progressed through mitosis to the subsequent G1 phase
(Fig. 3A). A dose of 4 M increased the G2/M delay to4 h. The ability
of CDK4i to inhibit G2/M progression was also observed with two other
cell lines, the melanoma cell lines A2058 and SK-Mel-13 (Fig. 3B). The
latter has a functional Rb-dependent G1 arrest, whereas the former is
defective for the checkpoint. There was little effect on S phase progres-
sion observed with any of the cell lines examined. The G2/M delay was
dependent on the addition of CDK4i during early S phase. The addition
during mid-S phase (4 h) produced a shorter delay of up to 2 h, whereas
the addition in late S/G2 phase (6 h) had no effect on progression through
G2/M (Fig. 3A, data for A2058 and SKMel-13 not shown). Treatment with
inactive analogues had no effect on cell cycle progression.
To determine whether the G2/M delay was during G2 phase or mito-
sis, MPM-2 FACS was performed to specifically define the mitotic pop-
ulation. Control HeLa cells had begun to enter into mitosis by 8 h and
returned to G1 by 12 h, whereas cells treated with CDK4i delayed entry
into mitosis until 12 h post-release. This indicated that CDK4i-treated
cells were delayed in G2 phase (Fig. 3C). This G2 delay was confirmed by
cyclin A-CDK2 and cyclin B1-CDK1 kinase assays. The delay corre-
sponded to an accumulation of phosphotyrosine 15 CDK1 and CDK2
observed by immunoblottingwith a phosphospecific antibody (Fig. 3D).
Cyclin B1 accumulated normally in the CDK4i-treated cultures (Fig.
3D) as did cyclin A (see Fig. 7A); thus, the blockade was due to failure to
dephosphorylate the inhibitory phosphotyrosine 15 residue on CDK2
and CDK1. The activation of the G2 phase pool of cyclin A-CDK2 and
G2/Mcyclin B1-CDK1 inCDK4i-treated cultureswas also delayed com-
paredwith untreated controls (data not shown). The inhibition of phos-
photyrosine 15 dephosphorylation on both CDK1 and CDK2 was sim-
ilar to that observed in theG2 arrests imposed byDNAdamaging agents
such as ionizing radiation, etoposide, and ultraviolet radiation (16),
which utilize stress checkpoint signaling pathways involving either
ATM, ATR, or p38 MAPK (17, 18). The addition of either caffeine to
inhibit ATM/ATR signaling or the p38 MAPK inhibitor SB203580 had
no effect on the G2 delay observed with CDK4i addition. However, both
these drugs did advance entry into mitosis in the controls by 1 h (Fig.
3E). The lack of effect of either inhibitor on theCDK4i-inducedG2 delay
suggests that does not operate through known DNA damage or stress
checkpoint pathways. When the level of the Wee1 kinase, which phos-
phorylates the inhibitory tyrosine 15 residue on CDK1 and CDK2, was
examined, it was found to decrease in inactive compound-treated con-
trols as they progressed into mitosis as expected, but in CDK4i-treated
samplesWee1 levels appeared to increase and stabilize for the duration
of theG2 phase delay, whichmay represent an alternativemechanismby
which the G2 delay was imposed (Fig. 3F).
The fate of individual cells after CDK4i treatment as they progressed
into and through mitosis was examined using time-lapse microscopy.
Control cells enteredmitosis at 8–9 h post-release with a high degree of
synchrony. In contrast, CDK4i-treated cells began entry into mitosis
11 h post-release (Fig. 4A). There was also a difference in the time the
cells remained in mitosis, with control cells requiring 78  51 min to
reach anaphase/telophase, whereas CDK4i-treated cells required 152
97min. The broader spread of time required to reach anaphase was due
to a subpopulation of cells that delayed longer in mitosis (Fig. 4B). In
addition, 20% of cells failed to undergo cytokinesis correctly in the
CDK4i-treated cultures, with the cells re-joining and forming large
multinuclear cells (Fig. 4C). This was only rarely observed in the control
cultures.
Specific siRNA Knockdown of Cyclin D3 Produces a Similar G2 Delay—
Although a panel of more than 80 protein kinases were examined for inhi-
bition by the twoCDK4i, it is still possible that the delay seenwas due to an
unknown effect of the drug. To exclude this possibility, siRNA knockdown
FIGURE 2. CDK4 Inhibitors Causes a G1 arrest in an Rb-dependent manner. A, asyn-
chronously growing HeLa cells (Rb-deficient) and melanoma cell line SK-Mel-13 (Rb-
competent) were treated for 24 h with 2 M CDK4i or inactive analogue (CDK4i) then
analyzed by FACS for DNA content. The percentage in each cell cycle phase and sub-
diploid (2 n), representing the dead population, is shown. B, asynchronous cultures of
HCT-116 cells were treated with increasing doses of CDK4i for 24 h. Cells were then
incubated with BrdUrd for 30min before harvesting for FACS. The percentage of cells
staining positive for BrdUrd is indicated. IC50 for RO05050124 used in this experiment
was 3.9 M; IC90 was 6.1 M. DMSO, dimethyl sulfoxide. C, asynchronous HCT-116 cells
were treated with increasing doses of CDK4i as in panel B for either 4 or 24 h before
harvesting for immunoblot analysis with phospho-Rb (Ser-795).
TABLE 2
CDK4i inhibits proliferation of cell lines
Proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MMT) assay 48 h after drug addition. The data are the mean of two
separate determinations performed in duplicate.
Cell line Inhibition IC50RO0505124 RO0506220
M
Colon
HCT116 3.85 1.10
RKO 1.60 0.54
SW480 3.67 1.06
COLO205 2.04 0.56
Breast
MDA-MB-435 3.06 1.20
MDA-MB-453 1.45 0.71
Lung
H460a 8.12 1.14
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of cyclin D3, the partner of G2 phase CDK4 identified in previous studies
(9), was used to inhibit CDK4 activity, and the effects onG2/Mprogression
was assessed. Three siRNA were designed against target sequences in the
C-terminal, N-terminal, central region of cyclin D3. All three siRNAs pro-
duced specific knockdown of cyclin D3 at a concentration of 10–20 nM at
24hpost-transfection,withprotein levels beginning to recover by 48h (Fig.
5, A and B). The levels of cyclin D1, E, A (not shown), and B1 (Fig. 5A)
remained unaffected by the siRNA transfection, indicating that the knock-
down was specific for cyclin D3. The three cyclin D3 siRNA produced
similar cell cycle effects so only the data for siRNA number 1 is shown. To
examine the effect of cyclin D3 knockdown in synchronized, transfected
HeLa cells, FACS analysis and time-lapse microscopy was performed. The
FIGURE 3. Inhibition of CDK4 results in a G2 delay. A, HeLa cells were synchronized using a double thymidine block releasemethod. Cells were treated at 2, 4, and 6 h post-release
with 2MCDK4iwith 2M inactive analogue (CDK4i) orwithout (Control). A slowdown throughG2/Mphase is observedwhen the drugwas addedbefore 4 hpost-release. B, A2058
andSK-Mel-13 cellswere synchronizedusing2mMhydroxyurea. 1hafter release cellswere treatedwith2MCDK4i orwithout (Con) and thenharvested forDNAFACSat the indicated
times post-release. The proportion of G1, S phase, and G2/M phase cells is indicated. C, HeLa cells were synchronized using a double thymidine block release method. At 1 h
post-release they were treated with 2 M CDK4i. Cells were then harvested at the indicated times post-release and analyzed for MPM-2 positive cells and DNA content using FACS.
D, synchronized HeLa cells treated with CDK4i in early S phase or untreated controls were harvested at the indicated times after release and analyzed by immunoblotting for cyclin
B1, phosphotyrosine 15 CDK1/2 (PY15), or cyclin D3 as a loading control. Peakmitosis was at 9–10 h in the controls and 12–14 h in CDK4i treated cultures. E, synchronized HeLa cells
treated with either inactive compound or CDK4i in early S phase and 20 M p38 MAPK inhibitor SB203580 (p38i) or 5 mM caffeine to inhibit ATM/ATR activity was added at 8 h after
synchrony release (G2 phase), then harvested at 12 h after release for FACS analysis. In this experiment peak mitosis was at 10 h. F, similar samples to those used in D were
immunoblotted for Wee1.
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results were essentially identical to the CDK4i-treated cells. Cyclin D3
knockdown delayed entry into mitosis by more than 2 h compared with
control cells (Fig. 5,C andD). To demonstrate that the delay observedwith
the CDK4i was due to specific inhibition of CDK4, synchronized cultures
treatedwith bothCDK4i and cyclinD3 siRNAwere analyzed by time-lapse
microscopy. Simultaneous treatment with CDK4i and cyclin D3 knock-
downproducedanonly slightly longerdelay than the individual treatments,
probably due to less than complete inhibition of CDK4with the individual
treatments (Fig. 5C). The lack of additive effect of theCDK4i and cyclinD3
knockdown demonstrated that the CDK4i drugs specifically inhibited
CDK4-cyclin D3 activity that was responsible for the cell cycle delays
observed.
CDK4-inhibited Cells Undergo Aberrant Mitosis—Time-lapse data
revealed that 20% of CDK4i-treated cells failed to undergo mitosis cor-
rectly, forming large multinuclear cells, suggesting that drug treatment
disrupted normal mitosis. Control and drug- and siRNA-treated cul-
tures were fixed as they progressed through mitosis, stained for micro-
tubules andDNA, and examined by fluorescencemicroscopy. Both con-
trol and CDK4i-treated cells had well-formed bipolar mitotic spindles.
However, 40% of CDK4i-treated cells displayed an aberrant mitotic
phenotype, characterized by lagging chromosomes, which often deco-
rated the astral side of the spindle microtubules (Fig. 6, A and B). These
lagging chromosomes were also visualized by time-lapse microscopy of
GFP-H2B-expressing HeLa cells, where these chromosomes formed
micronuclei after mitotic exit (Fig. 6C). A similar spectrum and level of
mitotic aberrations was observed in the cyclin D3 siRNA-treated cells
(data not shown). Examination of cells at 24 h after synchrony release
when themajority of cells have returned to interphase revealed that 30%
of CDK4i-treated cells containedmultiple nuclei andmicronuclei com-
pared with 10% in control cultures (Fig. 6D). These nuclear defects are
an indicator of mitotic failure and were likely to be the consequence of
the failed mitosis.
Inhibition of S/G2 CDK4/Cyclin D3 Delays Expression of Chromo-
somal Passenger Proteins—The failure of mitosis and defects in cyto-
kinesis detected by time lapse and fluorescent microscopy suggested
that there were possibly defects in the mechanisms controlling the
fidelity of mitosis, either the spindle assembly checkpoint or the
chromosomal passenger proteins such as survivin, aurora B, or
borealin, which form a complex with INCENP at the centromere that
FIGURE 4. Inhibition of CDK4 affects G2/Mprogression. A, time-lapsemicroscopywas
performed on synchronized HeLa cells treatedwith or without 2M CDK4i. Mitotic entry
counts were then performed with50 cells per field, scored with a minimum of 3 inde-
pendent fields for both control (Con) and CDK4i-treated cells counted. This is represent-
ativeof three separate experiments.B, time required for cells toprogress throughmitosis
until anaphase is shown. These data are representative of three separate experiments.
C, time lapse sequence of either control or CDK4i-treated cells progressing into and
through mitosis. The two CDK4i-treated cells progressed through mitosis with similar
timing to the control, but these cells both failed cytokinesis and eventually rejoined to
form a single binuclear cell.
FIGURE5. siRNAknockdownof cyclinD3phenocopiesCDK4i.A, HeLacellswere trans-
fected with various doses of cyclin D3 siRNA number 1, 20 nM concentrations of a non-
sense scrambled version of the cyclin D3 siRNA (NS) or without any siRNA (Lipo) and
harvested 24 and 48 h post-transfection. Cell lysates were immunoblotted for cyclin D3
and cyclin B1, which served as both a loading and siRNA specificity control. B, HeLa cells
were transfected with 20 nM concentrations of each of the three different cyclin D3
siRNAs, then harvested at 24 h and immunoblotted for cyclin D3 knockdown. C, HeLa
cells transfected with 20 nM cyclin D3 siRNA number 1 or with a scrambled siRNA (Con-
trol), then synchronized using hydroxyurea. After release, cells were harvested at the
indicated time points for FACS analysis of DNA content.D, synchronized HeLa cells were
either untreated (Control) or treatedwithCDK4i, cyclinD3 siRNAnumber 1 (D3), or CDK4i
and siRNA, and their progression into mitosis was followed by time lapse microscopy.
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influences spindle checkpoint function (19). The mitotic delay
detected after CDK4i treatment indicated that the spindle check-
point was functioning, and CDK4i treatment did not affect the ability
of nocodazole to arrest cells in mitosis (data not shown). However,
the presence of cells with multiple nuclei and micronuclei is evi-
dence that cells exited mitosis prematurely, indicating that the
checkpoint eventually failed. Knockdown of survivin or borealin or
inhibition of aurora B activity result in similar mitotic aberrations
and failure of cytokinesis as seen with CDK4i (13, 20, 21). Examina-
tion of total levels of survivin revealed that the normal G2/M accu-
mulation of survivin protein, which peaked at 10 h, was delayed in
the drug-treated cells (Fig. 7A). In controls, survivin continued to
accumulate until peak mitosis 10 h in this experiment, when cyclin A
levels started to diminish. In CDK4i-treated cells, survivin levels did
not reach control mitotic levels even at 14 h, which corresponded to
peak mitosis. When the levels of three of the mitotic passenger pro-
teins were examined in a separate experiment, the accumulation of
both survivin and borealin were delayed and failed to reach control
mitotic levels (Fig. 7B). The level of aurora B was unchanged across
mitosis, and CDK4i treatment had no affect. Similar results were
obtained using cyclin D3 knockdown (Fig. 7C). To determine
whether the delay and reduction in survivin accumulation in CDK4-
inhibited cells was due to reduced transcription, real time RT-PCR
analysis of the mRNA levels of survivin was performed. In control
cells the expected increase in survivin mRNA was observed, with the
peak corresponding to peak mitosis at 12 h (Fig. 7D). In both the
CDK4i- and siRNA-treated cells there was little reduction in survivin
mRNA levels, although these remained elevated longer probably due
to the delay in mitosis. Borealin mRNA behaved in an identical man-
ner (data not shown).
The localization of survivin is very characteristic, accumulating at
the centromeres in early mitosis then relocating to the midline of the
cells on the mid-spindle during anaphase and telophase, then deco-
rating the midbody in cytokinesis (19, 22). All of the chromosomal
passenger proteins localize identically through mitosis (19). Immu-
nofluorescent staining of mitotic cells for survivin did reveal an
increased proportion of mitotic cells with low levels of survivin stain-
ing and aberrant mitosis (Fig. 8A). When the cells with low survivin
levels were quantitated, the proportion displaying aberrant mitosis
increased from 9% in controls to 18% in CDK4i-treated cultures, but
FIGURE 6. CDK4i induce an aberrant mitosis.
A, HeLa cells were grown on coverslips and syn-
chronized using a double thymidine block release.
At 1 h post-release they were treated with 2 M of
CDK4i. Coverslips were harvested, and cells were
fixed as they progressed intomitosis,9 and 12 h
post-release for control and CDK4i-treated cells,
respectively. Cells were then stained for -tubulin
and 4,6-diamidino-2-phenylindole for DNA. B, cell
counts were performed on mitotic cells from A.
Each cell was visually inspected for normal met-
aphase congression or the presence of lagging
chromosomes, and the percentage of aberrant
mitosis is reported. The number of mitotic cells
counted is shown in parentheses. C, two CDK4i-
treated GFP-H2B-expressing HeLa cells progress-
ing throughmitosis. Note that the cells delayed in
mitosis for an extended period compared with
controls. In the top panel a chromosome fragment
fails to congress to themetaphase plate and forms
a micronucleus in one of the daughter cells (indi-
cated with the white arrow). In the bottom panel
chromosome fragments that fail to congress are
clearly seen. D, cells were treated as describe in A
but were harvested 24 h after release. Interphase
cells were then examined for the presence of
multi- andmicro nuclei and chromosome bridges,
as indicators of progression though an aberrant
mitosis. These data represent the three individual
experiments and are presented as the percentage
of total cells examined. The total number of cells
counted is shown in parentheses.
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there was a similarly increased proportion of cells with normal sur-
vivin staining and aberrant mitosis, from 7% in controls to 23% with
CDK4i treatment (Fig. 8B). This suggests that reduced chromosomal
passenger protein levels are unlikely to be the major determinant of
the aberrant mitosis in CDK4i-treated cells.
DISCUSSION
The function of CDK4-cyclin D has been defined in terms of its G1
phase role in regulating the activity of pocket proteins and thereby con-
trolling the transcription of genes required for progression into S phase.
However, there is evidence of a role for CDK4 later in the cell cycle.
CDK4 activity has been demonstrated in S and G2 phase (9, 23, 24), and
this activity is inhibited in UV-irradiated G2 phase-delayed cells, asso-
ciated with increased p16INK4A and loss of CDK4 phosphorylation (9).
We have now demonstrated that inhibition of CDK4-cyclin D activity
using either highly selective low molecular weight inhibitors or by
siRNA knockdown of the S/G2 phase CDK4 cyclin partner, cyclin D3,
causes a delay in entry into mitosis. The specificity of the drugs for
inhibiting CDK4-cyclin D3 in S/G2 phase was demonstrated by the
similarity of the effects of CDK4i addition and siRNA knockdown of
cyclin D3, the CDK4 partner in S/G2 phase. Furthermore, we have used
three different cyclin D3 target sequences to knock down cyclin D3,
which all produced similar cell cycle effects. Finally, CDK4i addition to
cyclin D3 knockdown cells did not significantly increase the G2 delay
observed with either treatment alone, indicating they both inhibit the
same target.
The G2 phase delay corresponds to a block in the cdc25-dependent
activation of CDK2-cyclin A and CDK1-cyclin B, similar to the geno-
toxin-induced G2 delay reported previously (16). Surprisingly, it does
not appear to be imposed by the characterized G2 checkpoint mecha-
nisms involving ATM/ATR or p38 MAPK. Interestingly, an increase in
the level of the CDK inhibitory kinase Wee1 was detected. This simply
may be a consequence of inhibition of proteasome-mediated destruc-
tion, which normally occurs as cells enter mitosis (25). However, a sim-
ilar accumulation of Wee1 has been reported elsewhere, and it may
represent an alternative target for G2 checkpoint controls (26). The
length of the delay is dependent on the degree of CDK4 inhibition, as
doubling the dose of CDK4i significantly increased the duration of G2
delay up to 12 h in some experiments, suggesting that CDK4 activity is
rate limiting for G2/M progression. Thus, inhibition of CDK4-cyclin D3
activity during S and G2 phase does delay G2-phase progression. How-
ever, themechanismof the delay is at present unclear. This suggests that
CDK4-cyclin D3 has an important function during S phase that directly
impacts on G2/M progression.
The effect of inhibition of CDK4-cyclin D3 activity on mitosis was
unexpected. Inhibition resulted in a significant increase in the pro-
portion of cells undergoing an aberrant mitosis characterized by
lagging chromosomes. This generally was only one or two chromo-
somes as compared with the major failure of chromosome congres-
sion at metaphase observed with either mutation, inhibition of kin-
etochore-associated mitotic spindle checkpoint-associated proteins
(21, 27, 28), or drugs that affect chromatin structure (14). The lag-
ging chromosomes initiate a mitotic checkpoint delay, demonstrated
by the increased time the CDK4i-treated cells require to reach
anaphase. Immunostaining for the presence of MAD2, a spindle
checkpoint component, revealed its localization to the kinetochores
of lagging chromosomes, a marker of activation of the spindle assem-
FIGURE 7. CDK4i treatment delayed and reduced the accumulation of survivin and
borealin. A, HeLa cells were synchronized using a double thymidine block release and
treated with 2 M CDK4i in early S phase. Cells were harvested at the indicated times
post-release for immunoblot analysis of the indicated proteins. Cyclin D 3 was used as a
loading control. This is representative of five separate experiments. B, in an experiment
similar to A, lysates were immunoblotted for the levels of the indicated chromosomal
passenger proteins. In this experiment peak mitosis was at 10–12 h in the controls and
13–14 h in the CDK4i-treated cultures. C, synchronized HeLa cells either pretreated with
cyclin D3 siRNA number 1 or scramble siRNAwere harvested at the indicated times after
synchrony release and immunoblotted for the indicated proteins. CDK2 was used as a
loading control. Peak mitosis was at 12 h in the scrambled control and 14 h in the cyclin
D3 siRNA treated cultures. D, quantitative real time RT-PCR for survivin was performed
using mRNA prepared from samples from the experiment shown in B. The data are the
average of triplicate determination. These data are representative of three separate
experiments.
FIGURE 8. CDK4i does not affect mitotic levels of survivin. A, immunofluorescence of
either control or CDK4i-treated cells stained for DNA, microtubules (-tubulin), and sur-
vivin. These represent typical normal survivin staining (control and right column of
CDK4i-treated) and low survivin staining (left column of CDK4i-treated). B, percentage of
cells displayingnormal or aberrantmitotic phenotype and their level of survivin staining.
124 controls (con) and 266 CDK4i-treated mitotic cells were counted.
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bly checkpoint (29).4 However, the spindle checkpoint eventually
fails as there was a significant increase in the proportion of cells that
exited mitosis without properly segregating their chromosomes, evi-
dent as cells with multiple and micronuclei. This appears to be an
example of mitotic slippage where the spindle checkpoint is initiated
but fails to maintain the arrest, resulting in cells prematurely exiting
mitosis (30) (31). The chromosomal passenger complex consisting of
INCENP, aurora B, survivin, and borealin, influences the localization
and operation of the kinetochore-associated mitotic spindle check-
point components such as MAD2 and BUBR1, thereby affecting
spindle checkpoint function (13, 19–21). The chromosomal passen-
gers accumulate at the centromere in prophase of mitosis, and each
chromosomal passenger influences the localization and activity of
the other passenger proteins (19). We have found that G2/M phase
accumulation of two of the chromosomal passenger complex, sur-
vivin and borealin, was delayed, but there was little reduction in the
levels of survivin or borealin that localized at centromeres of mitotic
cells after CDK4i treatment, indicating that these proteins are likely
to function normally. The reduced accumulation of these proteins
observed by immunoblotting is likely the consequence of a loss of
synchrony of the CDK4i-treated samples. The level of aurora B was
unaffected after CDK4i treatment, and we found no effect on aurora
B activity with normal levels of histone H3 Ser10 phosphorylation
detected (data not shown). Thus, the mechanism by which S/G2
CDK4-cyclin D3 influences the fidelity of mitosis remains unclear.
However, it does appears not to involve regulating the expression of
the chromosomal passenger protein.
A possible explanation for the mitotic defects is that they are a con-
sequence of a failure to stably arrest in G2 phase after CDK4i treatment.
Mitotic defects are a common feature of cells that fail to stably arrest
after exposure to ultraviolet radiation (32) or treatment with histone
deacetylase inhibitors (14). In these cases it is likely that some form of
either DNA damage or defective chromatin structure is responsible for
the mitotic defects. The source of defects after CDK4i treatment is at
present unclear.
The regulation of the CDK4-cyclin D/p16INK4A axis is often dis-
rupted in a wide variety of cancers, particularly melanomas, by either
mutation deletion or overexpression of various components (4). This
has generally been attributed to dysregulation of the G1-phase Rb-
dependent checkpoint. Although there is no doubt of the importance
of this effect, it is also possible that dysregulation of CDK4 may
influence other cell cycle phases. In this report we have demon-
strated that CDK4 has a critical role in ensuring the fidelity of mitotic
partitioning of the replicated genome. We have previously reported
that in epidermal-derived cell lines that the S/G2 phase CDK4 activ-
ity is inhibited by increased p16INK4A levels in response to subery-
themal doses of ultraviolet radiation (9) and that increased p16INK4A
expression correlated with a G2 phase delay in irradiated human skin
(33, 34). Inhibition of CDK4-cyclin D3 activity can delay progression
through G2 and is likely to contribute to the G2 delay observed after
exposure to ultraviolet radiation. P16INK4A inhibition of CDK4 in
this response may also regulate pathways that influence the fidelity
of mitosis. The failure to inhibit CDK4-cyclin D3 may result in cells
that are capable of transiting mitosis with mutant DNA and surviv-
ing to pass their mutations to future generations, thereby contribut-
ing to melanoma.
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Supplementary Table 1 
 
The Cdk4 inhibitor, RO0505124, was screened against Ambit’s panel of 128 kinases (35). A primary 
screen was performed at 1 micromolar, and the results reported as ‘% Competition’. High scores 
indicate strong screening hits. For kinases not hit in the primary screen at this concentration, a score of 
‘<50’ was assigned.  Quantitative binding constants (Kd’s) were not determined on any of the kinases 
scored as hits in the primary screen. 
 
Kinase Target 
Ambit Gene Symbol 
% 
Competition 
@ 1 µM 
AAK1 84 
ABL1 <50 
ABL2 <50 
ACK1 <50 
AKT1 <50 
AMPK-alpha1 <50 
AURKA <50 
AURKC <50 
BIKE <50 
BLK <50 
BMX <50 
BRAF <50 
BRAF(V600E) <50 
BTK <50 
CAMK1 <50 
CAMK1D <50 
CAMK1G <50 
CAMK2A <50 
CAMK2B <50 
CAMK2D <50 
CAMK2G <50 
CAMKK1 <50 
CAMKK2 <50 
CDK5 <50 
CLK1 100 
CLK2 100 
CLK3 89 
CLK4 97 
CSK <50 
CSNK1E <50 
CSNK1G1 98 
CSNK1G2 99 
CSNK2A1 <50 
DAPK2 <50 
DAPK3 <50 
DMPK <50 
EGFR <50 
EPHA2 <50 
EPHA3 <50 
EPHA4 <50 
EPHA5 <50 
EPHA6 <50 
EPHA7 <50 
  15
EPHA8 <50 
EPHB1 <50 
EPHB4 <50 
ERBB2 <50 
ERBB4 <50 
ERK2 <50 
FER <50 
FES <50 
FGFR1 <50 
FGFR2 <50 
FGFR3 <50 
FGR <50 
FLT3 <50 
FLT4 <50 
FRK <50 
FYN <50 
GAK 100 
HCK <50 
IGF1R <50 
INSR <50 
ITK <50 
JAK1(Kin.Dom.1) 94 
JAK2(Kin.Dom.2) <50 
JNK1 <50 
JNK2 <50 
JNK3 66 
KIT <50 
LCK <50 
LIMK1 <50 
LTK <50 
LYN <50 
MAP3K4 <50 
MAP4K5 <50 
MARK2 <50 
MKNK2 <50 
MYLK2 <50 
NEK2 <50 
NEK6 <50 
NEK9 <50 
p38-alpha <50 
p38-beta <50 
p38-gamma <50 
PAK1 <50 
PAK3 <50 
PAK4 <50 
PAK6 <50 
PAK7/PAK5 <50 
PCTK1 99 
PDGFRA <50 
PDGFRB <50 
PDPK1 <50 
PHKG1 <50 
PHKG2 <50 
PIM2 <50 
  16
PKAC-alpha <50 
PKMYT1 <50 
PLK4 <50 
PTK2 <50 
PTK2B <50 
PTK6 <50 
RAF1 <50 
RIPK2 <50 
ROS1 <50 
RPS6KA2(Kin.Dom.1) <50 
RPS6KA3(Kin.Dom.1) <50 
RPS6KA5(Kin.Dom.1) <50 
SLK 99 
SRC <50 
STK10 <50 
STK11 <50 
STK16 87 
STK17A 89 
STK17B <50 
STK3 <50 
STK36 86 
STK4 <50 
SYK <50 
TIE2 <50 
TNIK <50 
TRKA <50 
TTK 78 
TXK <50 
ULK3(mouse) <50 
VEGFR2 <50 
YES <50 
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